Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Pediatr. 2013 Apr;25(2):209-15. doi: 10.1097/MOP.0b013e32835df48a.

Complement disorders and hemolytic uremic syndrome.

Author information

  • 1Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, Texas 75390-9063, USA.

Abstract

PURPOSE OF REVIEW:

Complement mediated hemolytic uremic syndrome (aHUS) accounts for a significant proportion of non-shiga toxin HUS. The purpose of this review is to outline the pathophysiology, clinical features and therapeutic options for aHUS.

RECENT FINDINGS:

In the last decade, strides have been made in identifying several new disease-causing mutations in complement-regulating proteins.

SUMMARY:

Complement mediated HUS (aHUS) has a worse prognosis compared with shiga toxin mediated HUS, often resulting in end stage renal disease. Early identification of aHUS is crucial so that plasma therapy can be initiated. After renal transplantation, there is very high risk of disease recurrence and graft loss. Eculizumab and combined liver-kidney transplantation offer promise for improved prognosis.

PMID:
23399570
PMCID:
PMC3758882
DOI:
10.1097/MOP.0b013e32835df48a
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Support Center